Table 3.

Associations between statin use, dose and type, and prostate cancer aggressiveness, overall and stratified by race

AllCAAA
n, cases (aggressive)ORa (95% CI)ORb (95% CI)n, cases (aggressive)ORa (95% CI)ORb (95% CI)n, cases (aggressive)ORa (95% CI)ORb (95% CI)
Statin use
 No use1,205 (233)1.00 (ref)1.00 (ref)604 (99)1.00 (ref)1.00 (ref)601 (134)1.00 (ref)1.00 (ref)
 Use725 (111)0.68 (0.53–0.87)0.74 (0.56–0.96)408 (52)0.65 (0.45–0.93)0.64 (0.44–0.95)317 (59)0.73 (0.51–1.03)0.84 (0.58–1.21)
Statin dosec
 No use1,205 (233)1.00 (ref)1.00 (ref)604 (99)1.00 (ref)1.00 (ref)601 (134)1.00 (ref)1.00 (ref)
 Low/normal306 (45)0.65 (0.45–0.92)0.70 (0.49–1.01)180 (24)0.68 (0.42–1.11)0.66 (0.40–1.09)126 (21)0.64 (0.38–1.06)0.74 (0.43–1.26)
 High419 (66)0.70 (0.52–0.95)0.76 (0.55–1.04)228 (28)0.62 (0.39–0.98)0.63 (0.39–1.01)191 (38)0.79 (0.53–1.19)0.90 (0.59–1.38)
Statin typed
 No use1,205 (233)1.00 (ref)1.00 (ref)604 (99)1.00 (ref)1.00 (ref)601 (134)1.00 (ref)1.00 (ref)
 Hydrophilic132 (16)0.53 (0.31–0.91)0.56 (0.32–0.99)81 (8)0.48 (0.22–1.05)0.45 (0.20–1.00)51 (8)0.62 (0.29–1.36)0.72 (0.32–1.62)
 Lipophilic591 (94)0.71 (0.54–0.92)0.77 (0.58–1.02)327 (44)0.69 (0.46–1.02)0.69 (0.46–1.04)264 (50)0.74 (0.51–1.07)0.86 (0.58–1.27)
  • aAdjusted for age only.

  • bAdjusted for age, race (except for analyses stratified by race), site, BMI, cholesterol intake, percent saturated fat intake, smoking status, and prostate cancer screening frequency.

  • cLow/normal dose ≤20 mg simvastatin or equivalent; high dose > 20 mg simvastatin or equivalent.

  • dHydrophilic = rosuvastatin and pravastatin; lipophilic = atorvastatin, simvastatin, lovastatin, and fluvastatin.